Sugemalimab
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Also known as: cejemly, CS1001, WBP3155
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Sugemalimab is a drug catalogued in DrugCentral. It was first approved by the EMA in 2024. DrugCentral lists 1 molecular target, including CD274. Recorded indications include Non-small cell lung cancer.
- Molecular targets: CD274 (1 listed in DrugCentral).
- Indications: Non-small cell lung cancer.
- ATC code: L01FF11 (PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Non-small cell lung cancer
Mechanism & targets
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Programmed cell death 1 ligand 1 | CD274 | other | Kd 8.86 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2024-07-24 | EMA | — | Cstone Pharmaceuticals Ireland Limited |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
L01FF11 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors |
Chemical structure
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | — |
| InChIKey | — |
| PubChem CID | 13444038 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Sugemalimab used for?
DrugCentral lists the following indications for Sugemalimab: Non-small cell lung cancer.
How does Sugemalimab work?
Its molecular targets in DrugCentral include CD274.
When was Sugemalimab first approved?
Sugemalimab was first approved by the EMA in 2024.
Browse: all drugs starting with S · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5849 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL4594535 — compound record and bioactivity
- PubChem CID 13444038 — chemical identifiers
- DrugBank DB16641 — drug record
- FDA UNII 90IQR2I6TR — substance identity
- UniProt Q9NZQ7 (CD274) — target protein
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.